GeneDx (WGS) News Today

$21.16
-0.19 (-0.89%)
(As of 05/15/2024 ET)
Casdin Capital, Llc Acquires 50,000 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) Director Casdin Capital, Llc bought 50,000 shares of GeneDx stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average price of $23.31 per share, with a total value of $1,165,500.00. Following the purchase, the director now owns 2,753,509 shares of the company's stock, valued at approximately $64,184,294.79. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
GeneDx (NASDAQ:WGS) Shares Down 3%
GeneDx (NASDAQ:WGS) Shares Down 3%
GeneDx (NASDAQ:WGS) Sets New 1-Year High at $22.75
GeneDx (NASDAQ:WGS) Sets New 52-Week High at $22.75
GeneDx (NASDAQ:WGS) Trading Down 7.2%
GeneDx (NASDAQ:WGS) Shares Down 7.2%
GeneDx (NASDAQ:WGS) Sets New 52-Week High Following Analyst Upgrade
GeneDx (NASDAQ:WGS) Sets New 12-Month High After Analyst Upgrade
GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $12,188.16 in Stock
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 1,104 shares of the company's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $11.04, for a total transaction of $12,188.16. Following the completion of the transaction, the chief financial officer now owns 30,836 shares of the company's stock, valued at approximately $340,429.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
TD Cowen Increases GeneDx (NASDAQ:WGS) Price Target to $24.00
TD Cowen boosted their target price on GeneDx from $14.00 to $24.00 and gave the stock a "buy" rating in a report on Tuesday.
GeneDx is about to announce its earnings — here's what to expect
GeneDx reports Q1 results
GeneDx Q1 2024 Earnings Preview
GeneDx Holdings Corp. (WGS)
BTIG Research Increases GeneDx (NASDAQ:WGS) Price Target to $15.00
BTIG Research raised their target price on shares of GeneDx from $11.00 to $15.00 and gave the company a "buy" rating in a research note on Monday.
GeneDx (NASDAQ:WGS) PT Raised to $11.00
The Goldman Sachs Group boosted their price objective on GeneDx from $6.00 to $11.00 and gave the stock a "neutral" rating in a report on Monday.
Kareem Saad Sells 2,008 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) insider Kareem Saad sold 2,008 shares of the firm's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $10.59, for a total transaction of $21,264.72. Following the transaction, the insider now directly owns 29,517 shares of the company's stock, valued at approximately $312,585.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
WGS Apr 2024 7.500 call
WGS Apr 2024 7.500 put
GeneDx Holdings Corp. Class A
Oracle Investment Management Inc. Boosts Position in GeneDx Holdings Corp. (NASDAQ:WGS)
Oracle Investment Management Inc. lifted its stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 14.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 994,580 shares of the company's stock after purchasing an additional
WGS Mar 2024 7.500 put
WGS Mar 2024 10.000 put
GeneDx Hldgs Stock (NASDAQ:WGS) Insider Trades
Here's what Wall Street expects from GeneDx's earnings
GeneDx Holdings Corp. (NASDAQ:WGS) Short Interest Update
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 1,060,000 shares, a growth of 6.9% from the January 15th total of 991,900 shares. Based on an average daily volume of 399,400 shares, the days-to-cover ratio is currently 2.7 days. Currently, 6.9% of the shares of the stock are sold short.
GeneDx (WGS) to Release Earnings on Tuesday
GeneDx (NASDAQ:WGS) will be releasing earnings after the market closes on Tuesday, February 20, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=560440)
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx Announces Preliminary 2023 Financial Results
Get GeneDx News Delivered to You Automatically

Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.

WATCH: The Truth About Inflation (Ad)

The full story on inflation is being CENSORED by the powers that be. But I have the REAL monthly numbers. And they are going to anger you. (Especially if you have money sitting in a 401k or IRA.)

WATCH: The Truth About Inflation

WGS Media Mentions By Week

WGS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

WGS
News Sentiment

1.14

0.54

Average
Medical
News Sentiment

WGS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

WGS Articles
This Week

5

1

WGS Articles
Average Week

Get GeneDx News Delivered to You Automatically

Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:WGS) was last updated on 5/16/2024 by MarketBeat.com Staff

From Our Partners